Sign in
4

Changes in Ownership

Mineralys Therapeutics, Inc. Filed Acc 0001816952-26-000002

Director sold 3,000 shares at $25.00 ($75,000)

  • Director acquired 3,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Karydas Daphne Director 2026-03-31 Option exercise 10b5-1 +3,000 $12.02 $36,060 9,200 D
Karydas Daphne Director 2026-03-31 Sale 10b5-1 −3,000 $25.00 $75,000 6,200 D
Derivatives
Karydas Daphne Director 2026-03-31 Option exercise · Stock Option 10b5-1 −3,000 41,000 D
Open-market sales · 3,000 sh · avg $25.00 · $75,000
Loading xslF345X06/wk-form4_1775170385.xml…